Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...

WHO has sounded alarm over a sharp spike in HIV cases in the Philippines, Fiji and Papua New Guinea, urging urgent prevention ...

More than 40 years have passed since the CDC reported the first cases of HIV in the United States. In that time, we’ve ...

People living with HIV who smoke are currently more likely to die from lung cancer than from HIV-related causes. Two cancer ...

Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for ...

"You know, it's not the best news. But there was other news that could have been a lot worse, you know?" Charlie Sheen said.

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain.

GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit ...

It found that across the 34 emergency departments taking part in the programme, 3,667 people were newly diagnosed with ...

There were still 32,000 new cases of HIV in the U.S. in 2022. And about thousands of people still die annually from AIDS. HIV ...

Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 ...

According to the new study, HIV achieves this with a tissue-specific approach, cloaking itself in a host cell's DNA by ...